PCSK9, the short track road from discovery as drug target towards the clinic
This lecture was part of a CME accredited symposium: PCSK9 inhibition in clinical lipid management: A critical review of evidence and opportunities held at ESC 2016 in Rome
Video navigation menu
- The discovery of PCSK9 - a brief overview 00:14
- Cardiovascular benefits of PCSK9 loss of function mutations 02:55
- The biology of PCSK9 04:12
- The development of PCSK9 inhibitors 08:34
- PCSK9 inhibitors also reduce Lp(a) by increasing its hepatic secretion 09:43
- Conclusion 12:36
Educational objectives of this symposium were to:
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
- Emphasize the need for outcomes data from clinical trials to apply implications and recommendations for practical lipid management
- Understand the implications of new ESC guidelines for lipid management
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Prof Gilles Lambert is Professor in Cell Biology and Biochemistry at the University of La Réunion Medical School (France) and a principal investigator at Inserm UMR1188 DéTROI.
Supported by unrestricted educational grants from Amgen, Pfizer, and Sanofi-Regeneron.